(Q45747018)

15 December 2017

title

Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy (English)

1 reference

15 December 2017

0 references

1 reference

1 reference

1 reference

Yeo W

1

1 reference

15 December 2017

Steinberg JL

2

1 reference

15 December 2017

Tam JS

3

1 reference

15 December 2017

Chan PK

4

1 reference

15 December 2017

Leung NW

5

1 reference

15 December 2017

Lam KC

6

1 reference

15 December 2017

Mok TS

7

1 reference

15 December 2017

Johnson PJ

8

1 reference

15 December 2017

publication date

1 November 1999

1 reference

15 December 2017

Journal of Medical Virology

published in

1 reference

15 December 2017

volume

59

1 reference

15 December 2017

issue

3

1 reference

15 December 2017

page(s)

263-269

1 reference

15 December 2017

Lamivudine treatment for acute hepatitis B after liver transplantation

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Progress on the control of hepatitis B infection through immunisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Treatment of HBV reactivation after withdrawal of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Hepatitis B infection in patients with lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Contrasting relations between suppressor-cell function and suppressor-cell number in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

A preliminary trial of lamivudine for chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Combination therapy for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Treatment of chronic hepatitis B with lamivudine in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Factors influencing response to interferon in chronic hepatitis B: Implications for Asian and western populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-9071%28199911%2959%3A3%3C263%3A%3AAID-JMV1%3E3.0.CO%3B2-X

10.1002/(SICI)1096-9071(199911)59:3<263::AID-JMV1>3.0.CO;2-X

21 January 2018

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017